Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Oxford BioTherapeutics
Oxford BioTherapeutics
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Boehringer Ingelheim receives US FDA Fast Track designation for BI 764532
BI 764532 is a potential treatment of advanced or metastatic large-cell neuroendocrine carcinoma of the lung
Research & Development
Oxford BioTherapeutics relocates UK headquarters to the Oxford Science Park
The new facilities comprise state-of-the-art office and custom laboratory spaces that will support and enhance OBT’s growing target discovery and drug development capabilities
Manufacturing
Oxford BioTherapeutics and Boehringer Ingelheim extend cancer immunology partnership
The two companies have extended their existing collaboration by a further two years, aiming to develop novel cancer immunotherapies
Research & Development
Boehringer Ingelheim and OBT advance oncology candidate
The Boehringer Ingelheim drug candidate was discovered in a partnership with Oxford BioTherapeutics and enabled by Oxford BioTherapeutics’ proprietary OGAP target discovery platform
Recruitment
Oxford BioTherapeutics appoints Chief Medical Officer
Research & Development
Oxford BioTherapeutics licenses Nerviano's drug-linker technology
To develop novel antibody drug conjugates
Research & Development
Oxford BioTherapeutics hires Head of Clinical Development
Dr Eugen Leo takes the position
Subscribe now